Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 38
1.
Br J Anaesth ; 121(3): 616-622, 2018 Sep.
Article En | MEDLINE | ID: mdl-30115260

BACKGROUND: Chronic pain is no longer an effective warning system, but a syndrome with co-morbidities and many causes, needing a careful evaluation. Questions remain about the pain behaviour of chronic pain patients compared with patients with acute pain, or healthy subjects that we investigated. METHODS: We compared three populations: healthy (HS, n=280), with acute pain (AP=110 patients), and chronic pain (CP=280 patients) by assessing their pain behaviour with the pain sensitivity questionnaire (PSQ-total and PSQ-minor). The influence of central sensitisation syndrome (CSS) on chronic pain behaviour, including catastrophising, was further investigated by using the central sensitisation inventory. RESULTS: Compared with the AP patients and HS, the CP patients exhibited significantly higher catastrophising scores; higher PSQ-minor scores [29.0 (21.0-39.0), than for AP 24.0 (14.0-32.5), and for healthy subjects 25.0 (17.0-34.0); and PSQ-total scores of for CP, 63.5 for AP, and 64.0 for HS. No significant difference was observed between the HS and AP populations. Significant differences were observed between the CP patients with and without CSS. The median PSQ-minor for patients with CSS was 33.0 and without CSS was 25.0 (P<0.05); the median PSQ-total for patients with CSS was 82.0 and without CSS was 65 (P<0.05). The CP patients without CSS did not show any significant difference compared with the AP and HS groups, except for catastrophising. CONCLUSIONS: This study highlights the influence of CSS in the results of PSQ and catastrophising by chronic pain patients in comparison with healthy controls and acute pain patients. CLINICAL TRIAL REGISTRATION: P2014/134.


Catastrophization , Chronic Pain/psychology , Pain Measurement/methods , Surveys and Questionnaires , Acute Pain/physiopathology , Adult , Case-Control Studies , Female , Humans , Internal-External Control , Male , Middle Aged , Nociception/physiology , Pain Threshold/physiology , Young Adult
2.
Br J Anaesth ; 118(3): 298-310, 2017 Mar 01.
Article En | MEDLINE | ID: mdl-28203792

Cardiac output (CO) measurement is crucial for the guidance of therapeutic decisions in critically ill and high-risk surgical patients. Newly developed completely non-invasive CO technologies are commercially available; however, their accuracy and precision have not recently been evaluated in a meta-analysis. We conducted a systematic search using PubMed, Cochrane Library of Clinical Trials, Scopus, and Web of Science to review published data comparing CO measured by bolus thermodilution with commercially available non-invasive technologies including pulse wave transit time, non-invasive pulse contour analysis, thoracic electrical bioimpedance/bioreactance, and CO2 rebreathing. The non-invasive CO technology was considered acceptable if the pooled estimate of percentage error was <30%, as previously recommended. Using a random-effects model, sd, pooled mean bias, and mean percentage error were calculated. An I2 statistic was also used to evaluate the inter-study heterogeneity. A total of 37 studies (1543 patients) were included. Mean CO of both methods was 4.78 litres min−1. Bias was presented as the reference method minus the tested methods in 15 studies. Only six studies assessed the random error (repeatability) of the tested device. The overall random-effects pooled bias (limits of agreement) and the percentage error were −0,13 [−2.38 , 2.12] litres min−1 and 47%, respectively. Inter-study sensitivity heterogeneity was high (I2=83%, P<0.001). With a wide percentage error, completely non-invasive CO devices are not interchangeable with bolus thermodilution. Additional studies are warranted to demonstrate their role in improving the quality of care.


Cardiac Output , Monitoring, Physiologic/instrumentation , Monitoring, Physiologic/methods , Perioperative Care/instrumentation , Perioperative Care/methods , Humans , Reproducibility of Results
3.
Acta Gastroenterol Belg ; 67(2): 176-8, 2004.
Article En | MEDLINE | ID: mdl-15285574

The Paediatric Liver Transplant Program at Saint-Luc University Clinics constitutes a substantial single centre experience, including 667 transplantations performed between March 1984 and April 2003, and the history of this program reflects the tremendous progress in this field since twenty years. Liver transplantation in children constitutes a considerable undertaking and its results depend on multiple, intermingled risk factors. An analysis of the respective impact of several surgical and immunological parameters on patient/graft outcome and allograft rejection after paediatric liver transplantation showed a significant learning curve effect as well as the respective impact of pre-transplant diagnosis on survival and of primary immunosuppression on the rejection incidence. The introduction of living related liver transplantation in 1993 not only permitted to provide access to liver replacement in as many as 74% more candidate recipients, but also resulted in better graft survival and reduced retransplantation rate. The results of a recent pilot study suggest that steroid avoidance is not harmful, and could even be beneficial for paediatric liver recipients, particularly regarding growth, and that combining tacrolimus with basiliximab (anti-CD25 chimeric monoclonal antibody) for steroid substitution appears to constitute a safe alternative in this context. The long-term issues represent the main future challenges in the field, including the possibility of a full rehabilitation through immunosuppression withdrawal and tolerance induction, the development of adolescence transplant medicine, and the risk of early atherogenesis in the adulthood.


Liver Transplantation/methods , Living Donors , Adolescent , Belgium , Child , Child, Preschool , Humans , Immunosuppressive Agents/therapeutic use , Infant
4.
Acta Gastroenterol Belg ; 67(2): 188-96, 2004.
Article En | MEDLINE | ID: mdl-15285577

The authors present the results of a single centre study of 587 liver transplants performed in 522 adults during the period 1984-2002. Results have improved significantly over time due to better pre-, peri- and post-transplant care. One, five, ten and fifteen year actuarial survivals for the whole patient group are 81.2; 69.8; 58.9 and 51.2%. The high incidence of de novo tumors (12.3%), of cardiovascular diseases (7.5%) and of end-stage renal function (3.6%) should be further incentives to tailor the immunosuppression to the individual patient and to direct the attention of the transplant physician to the long-term quality of life of the liver recipient.


Liver Transplantation , Adult , Humans , Immunosuppressive Agents/therapeutic use , Survival Analysis , Treatment Outcome
5.
Transplantation ; 72(2): 345-7, 2001 Jul 27.
Article En | MEDLINE | ID: mdl-11477367

BACKGROUND: Elevated right ventricle pressure resulting from pulmonary artery stenoses may affect outcome and survival after liver transplantation in patients with Alagille syndrome. METHODS AND RESULTS: Between 1984 and 1997, among 444 pediatric liver transplant recipients, 17 had liver transplantation for Alagille syndrome (mean age 3.5 years, range 1.2-13 years), mainly because of poor quality of life with intractable pruritus, and failure to thrive. All patients had pulmonary artery stenosis. In 10 patients considered to have elevated RV pressure on ECG and/or Doppler-echocardiography, a cardiac catheterization was performed before liver transplantation. Mean RV systolic pressure was 55 mmHg (median 49.5 mmHg, range 35-98 mm Hg), mean RV to left ventricular systolic pressure ratio 0.53 (median 0.53, range 0.29-0.78) with a ratio above 0.5 in 6 patients (median 0.66, range 0.5-0.8). All patients underwent successful liver transplantation. Five patients died 1 to 9 months after transplantation from noncardiac causes. In two of them, cardiac catheterization before transplantation showed a RV to left ventricular pressure ratio of 0.51 in one and 0.37 in the second. In the three others, echocardiography before transplantation estimated RV pressures below 0.5 systemic pressures. At follow-up (median 6 years, range 1.5-15 years), liver tests were normal in all, none complained of pruritus and body weight was normalized in 70%. None of the patients presented cardiac symptoms, arrhythmias, or worsening of their cardiac status. CONCLUSIONS: Liver transplantation can be performed safely in children with Alagille syndrome, even in the presence of elevated right ventricular pressure.


Alagille Syndrome/surgery , Arterial Occlusive Diseases/complications , Liver Transplantation , Pulmonary Artery , Ventricular Dysfunction, Right/physiopathology , Adolescent , Blood Pressure , Cardiac Catheterization , Child , Child, Preschool , Contraindications , Follow-Up Studies , Hemodynamics , Humans , Infant , Liver Transplantation/methods , Liver Transplantation/physiology , Time Factors , Ventricular Function, Left
6.
Acta Chir Belg ; 101(1): 17-9, 2001.
Article En | MEDLINE | ID: mdl-11301941

The Brussels series of living related liver transplantation (LRLT) in 77 children (< 15 years) is reviewed. Median (range) recipient age at liver transplantation was 1.1 year (0.4-13.1). The main indication for LT was biliary atresia in 55/77 cases (71%). The living-related donor was one of the parents in 74 instances. Hepatic segments 2-3 (n = 67) or 2-3-4 (n = 10) were implanted orthotopically, with a median (range) graft weight to recipient body weight ratio of 3.17% (0.91-8.08). No severe complications or significant long-term sequelae were encountered in the living donors. One and five year survival rates were 92% and 89% for the patients, and 90% and 86% for the grafts, respectively. The retransplantation rate was 2/77 (2.6%), the indication being chronic rejection in both instances. In conclusion, LRLT is now a validated procedure in the living donors as well as in pediatric recipients with chronic or acute liver diseases. In the current context of organ shortage, it provides a valuable alternative to cadaveric LT.


Liver Transplantation , Living Donors , Tissue Donors/supply & distribution , Adolescent , Belgium , Child , Child, Preschool , Female , Follow-Up Studies , Hepatectomy , Humans , Infant , Male , Postoperative Complications/etiology , Postoperative Complications/mortality , Reoperation , Survival Rate
8.
Anesthesiology ; 92(3): 683-6, 2000 Mar.
Article En | MEDLINE | ID: mdl-10719946

BACKGROUND: Sevoflurane is metabolized by cytochrome P450 and produces inorganic fluoride. The anhepatic phase of liver transplantation provides a useful tool to study the extrahepatic metabolism of drugs. The authors therefore studied the extrahepatic metabolism of sevoflurane by measuring the fluoride production in children receiving sevoflurane solely during the anhepatic phase of orthotopic liver transplantation. METHODS: Children with end-stage liver disease undergoing orthotopic liver transplantation were studied. Anesthesia was provided with isoflurane, sufentanil, and pancuronium. In one group, isoflurane was replaced by sevoflurane as soon as the liver was removed from the patient and maintained until reperfusion of the new liver. Arterial blood samples were drawn at induction, before removal of the liver, 15 min and 30 min after the beginning of the anhepatic phase, at the unclamping of the new liver, and finally 60 and 120 min after the unclamping. Plasma fluoride concentrations were determined by ion-selective electrode. RESULTS: No differences between the two groups (n = 10) regarding age, weight, duration of the anhepatic phase, or basal level of inorganic fluoride were found. The fluoride concentration increased significantly as soon as sevoflurane was introduced; it remained stable in the group receiving isoflurane. The peak fluoride concentration was also significantly higher in the first group (mean +/- SD: 5.5 +/- 0.8 microM (sevoflurane group) versus 1.4 +/- 0.5 microM (isoflurane group) P < 0.05). CONCLUSIONS: These results demonstrate the existence of an extrahepatic metabolism of sevoflurane at least in children with end-stage liver disease.


Anesthetics, Inhalation/pharmacokinetics , Liver Transplantation/physiology , Liver/metabolism , Methyl Ethers/pharmacokinetics , Anesthesia, Inhalation , Biliary Atresia/surgery , Child, Preschool , Fluorides/blood , Humans , Liver/physiology , Sevoflurane
10.
Anesth Analg ; 89(5): 1137-42, 1999 Nov.
Article En | MEDLINE | ID: mdl-10553824

UNLABELLED: Children with Alagille's syndrome are at increased perioperative risk during orthotopic liver transplantation due to the cardiopulmonary abnormalities and the hemodynamic changes associated with this procedure. We studied 16 children with Alagille's syndrome who underwent 21 orthotopic liver transplantations. Peripheral pulmonary stenosis was present in all subjects. Right ventricular pressures were increased in 15 cases. Caval clamping resulted in a mean decrease of 15 +/-9 mm Hg in systolic blood pressure, 5 +/- 3 mm Hg in mean pulmonary artery pressure, and 4 +/- 3 mm Hg in central venous pressure. Systolic blood pressure decreased by 16 +/- 13 mm Hg, whereas mean pulmonary artery pressure and central venous pressure increased by 3 +/- 4 mm Hg and 1 +/- 4 mm Hg, respectively, at portal vein unclamping. There was no correlation between severity of pulmonary artery stenosis and hemodynamic changes. Veno-venous bypass used in four cases resulted in smaller hemodynamic changes. Time to extubation and duration of intensive care unit stay were unrelated to severity of pulmonary artery stenosis. IMPLICATIONS: Some children with Alagille's syndrome require liver transplantation. In our study, associated pulmonary artery stenosis did not dramatically increase perioperative risk. Veno-venous bypass decreased intraoperative hemodynamic changes in these patients.


Alagille Syndrome/surgery , Hemodynamics , Liver Transplantation , Alagille Syndrome/complications , Alagille Syndrome/physiopathology , Blood Pressure , Central Venous Pressure , Child , Child, Preschool , Constriction, Pathologic , Female , Humans , Infant , Male , Pulmonary Artery/pathology , Pulmonary Artery/physiopathology , Retrospective Studies
11.
Acta Gastroenterol Belg ; 62(3): 306-18, 1999.
Article En | MEDLINE | ID: mdl-10547897

OBJECTIVE: To evaluate the impact of standardized operative and peri-operative care on the outcome of liver transplantation in a single center series of 395 adult patients. METHOD AND MATERIAL: Between February 1984 and December 31, 1998, 451 orthotopic liver transplantations were performed in 395 adult patients (> or = 15 years) at the University Hospitals St-Luc in Brussels. Morbidity and mortality of the periods 1984-1990 (Gr I--174 pat.) and 1991-1998 were compared (Gr II--221 pat.). During the second period anti-infectious chemotherapy and perioperative care were standardized and surgical technique changed from classical orthotopic liver transplantation with recipients' vena cava resection (and use of veno-venous bypass) towards liver implantation with preservation of the vena cava (without use of bypass). Immunosuppression was cyclosporine based from 1984 up to 1996 and tacrolimus based during the years 1997 and 1998. Immunosuppression was alleviated during the second period due to change from quadruple to triple and even double therapy and due to the introduction of low steroid dosing and of steroid withdrawal, once stable graft function was obtained. Indications for liver grafting were chronic liver disease (284 pat--71.9%), hepatobiliary tumor (52 pat--13.2%), acute liver failure (40 pat--10.1%) and metabolic disease (19 pat--4.8%). Regrafting was necessary because of graft dysfunction (21 pat), technical failure (12 pat), immunological failure (18 pat) and recurrent viral allograft disease (5 pat); three of these patients were regrafted at another institution. Follow-up was complete for all patients with a minimum of 9 months. RESULTS: Actuarial 1, 5 and 10 years survival rates for the whole group were 77.9%, 65.7% and 58.3%. These survival rates were respectively 77.3%, 69.7%, 62.5% and 73.2%, 59.6% 51.4% for benign chronic liver disease and acute liver failure; those for malignant liver disease were 80.6%, 44.3% and 36.7%. Early (< 3 months) and late (> 3 months) posttransplant mortalities were. 14.4% (57 pat) and 21.2% (84 pat). Early mortality lowered from 20% in Gr I to 9.4% in Gr II (p < 0.02); this was due to a significant reduction during the second period of bacterial (99/174 pat.--56.9% vs 82/221 pat.--37.1%), fungal (14 pat.--8% vs 7 pat.--3.2%) and viral (87 pat.--50% vs 49 pat.--22.2%) infections (p < 0.05) as well as of perioperative bleeding (92 pat.--52.9% vs 39 pat.--17.6%--p < 0.001). Late mortality remained almost identical throughout the two periods as lethal outcome was mainly caused by recurrent allograft diseases, cardiovascular and tumor problems. Morbidity in these series was important considering that almost, half of the patients had a technical complication, mostly related to bleeding (131 pat--33.2%) and biliary problems (66 pat--16.7%). Retransplantation index was 1.1 (54 pat.--14%). Early retransplantation mortality was 24%; it lowered, although not yet significantly, during the second period (8/25 pat.--32% vs. 5/29 pat.--17.2%). CONCLUSION: Despite a marked improvement of results, liver transplantation remains a major medical and surgical undertaking. Standardization of operative and perioperative care, less haemorraghic surgery and less aggressive immunosuppression are the keys for further improvement.


Liver Diseases/surgery , Liver Transplantation/statistics & numerical data , Adolescent , Adult , Aged , Belgium , Cost Control , Humans , Immunosuppression Therapy , Liver Transplantation/methods , Liver Transplantation/mortality , Middle Aged , Postoperative Complications/epidemiology , Survival Rate
12.
Pediatr Surg Int ; 13(5-6): 308-18, 1998 Jul.
Article En | MEDLINE | ID: mdl-9639606

Between 1984 and 1996, the authors performed 499 liver transplants in 416 children less than 15 years old. The overall patient survival at 10 years was 76.5%. It was 71.3% for the 209 children grafted in 1984-1990; 78.5% for biliary atresia (n = 286), 87.3% for metabolic diseases (n = 59), and 72.7% for acute liver failure (n = 22). The 5-year survival was 73.6% for the 209 children grafted in 1984-1990 and 85% for the 206 grafted in 1991-1996. Scarcity of size-matched donors led to the development of innovative techniques: 174 children who electively received a reduced liver as a first graft in our center had a 5-year survival of 76% while 168 who received a full-size graft had a survival of 85% (NS). Results of the European Split Liver Registry showed 6-month graft survival similar to results obtained with full-size grafts collected by the European Liver Transplant Registry. Extensive use of these techniques allowed the mortality while waiting to be reduced from 16.5% in 1984-1990 to 10% in 1991-1992. It rose again to 17% in 1993, leading the authors to develop a program of living related liver transplantation (LRLT). The legal and ethical aspects are analyzed. Between July 1993 and October 1997, the authors performed 53 LRLTs with 90% survival. In elective cases, a detailed analysis was made of the 45 children listed for LRLT between July 1993 and March 1997 and the 79 registered on the cadaveric waiting list during the same period. Mortality while waiting was 2% and 14.5% for the LRLT and cadaveric lists, respectively. The retransplantation rate was 4.6% and 16.1% for LRLT and cadaveric transplants, respectively. Overall post-transplant survival was 88% and 82% for children who received a LRLT or a cadaveric graft, respectively. Overall survival from the date of registration was 86% and 70% (P < 0.05) for LRLT or cadaveric LT respectively. The 2-year post-transplant survival in children less than 1 year of age at transplantation was 88.8% and 80. 3% with a LRLT or cadaveric graft, respectively; patient survival after 3 months post-transplant was 95.8% and 91.9% for stable children waiting at home, 93.7% and 93.7% in children hospitalized for complications of their disease, and 89.5% and 77.7% for children hospitalized in an intensive care unit at the time of transplantation for children who received a LRLT or cadaveric graft, respectively. It is concluded that LRLT seems to be justified for multidisciplinary teams having a large experience with reduced and split liver grafting.


Liver Transplantation/methods , Living Donors , Child , Humans , Liver Diseases/surgery , Liver Transplantation/mortality , Liver Transplantation/statistics & numerical data , Registries , Retrospective Studies , Survival Rate , Waiting Lists
13.
Paediatr Anaesth ; 8(1): 59-64, 1998.
Article En | MEDLINE | ID: mdl-9483600

Until recently, hypoxaemia was considered as a relative contraindication for liver transplantation. The hepatopulmonary syndrome associated with a right to left shunt of blood through the lungs is reversible in adults and children after correction of the cirrhosis by liver transplantation. However, concerns have been raised regarding the risks of anaesthesia in such hypoxaemic patients. Since the peroperative management of children undergoing liver transplantation and suffering from hepatopulmonary syndrome and severe hypoxemia has never been described, we report here our experience in seven children. Despite the fact that severe arterial desaturation was recorded throughout the procedure, no major complications were recorded peroperatively. The postoperative intubation time was 58 +/- 21 h, five children being extubated while still hypoxaemic. All seven patients reversed their hepatopulmonary syndrome after a mean postoperative period of 24 +/- 10 weeks. This shows that liver transplantation can be successfully achieved in severely hypoxaemic children and that postoperative correction of the right to left shunt is then obtained.


Hypoxia/etiology , Liver Cirrhosis/surgery , Liver Transplantation , Adolescent , Anesthesia , Blood Pressure , Child , Child, Preschool , Chronic Disease , Female , Humans , Hypoxia/blood , Liver Cirrhosis/complications , Liver Cirrhosis/physiopathology , Male , Oxygen/blood , Postoperative Complications , Preoperative Care , Pulmonary Artery , Pulmonary Circulation , Pulmonary Wedge Pressure
14.
Anesth Analg ; 86(3): 468-76, 1998 Mar.
Article En | MEDLINE | ID: mdl-9495395

UNLABELLED: In this prospective, nonblind study, we report the use of clonidine during orthotopic liver transplantation (OLT). Twenty adult patients in a stable medical condition were studied. General anesthesia consisted of isoflurane in air/oxygen and sufentanil. Patients in the clonidine group received a slow i.v. infusion (15 min) of 4 microg/kg clonidine during induction. The other patients were used as controls. I.v. fluid requirements were determined as follows: albumin (4% solution) was administered to maintain filling pressures to a pulmonary capillary wedge pressure (PCWP) of more than 12 mm Hg. Packed red blood cells were transfused to maintain a hemoglobin level of 8-9 g/dL. Circulatory stability was evaluated using: systolic and diastolic arterial blood pressure and heart rate recorded at 2-min intervals; and the vasopressor/inotropic support required to maintain adequate hemodynamic variables after reperfusion. Intraoperative albumin and packed red blood cell requirements were significantly reduced in patients in the clonidine group (1644 +/- 140 and 50 +/- 50 mL vs 2867 +/- 226 mL and 1350 +/- 443 mL; P < 0.05). Heart rate was significantly slower in patients of the clonidine group. There were no differences in systolic arterial blood pressure. After reperfusion, patients in the control group showed significantly lower diastolic arterial blood pressure, required more vasopressor/inotropic support, and were more acidotic than patients in the clonidine group. We conclude that the administration of 4 microg/kg clonidine during induction of OLT significantly reduced the intraoperative requirements of i.v. fluids and blood products without compromising circulatory stability. Improvement in immediate reperfusion-induced disturbances was observed. IMPLICATIONS: The administration of 4 microg/kg clonidine during induction of liver transplantation significantly reduced the intraoperative requirements for i.v. fluids and blood products without compromising the circulatory stability. Improvement in immediate reperfusion-induced disturbances was also observed.


Clonidine/therapeutic use , Liver Transplantation/methods , Blood Volume , Cardiac Output , Diuresis , Hemodynamics , Humans , Hydrogen-Ion Concentration , Injections, Intravenous , Lactates/blood , Middle Aged , Potassium/blood , Prospective Studies , Water-Electrolyte Balance
16.
Br J Anaesth ; 77(2): 227-31, 1996 Aug.
Article En | MEDLINE | ID: mdl-8881631

We have studied the effect of combining inhaled nitric oxide (NO) with an i.v. vasodilator agent, nitroglycerin, or ciloprost, a prostacyclin analogue, during acute pulmonary hypertension in pigs, induced by continuous infusion of a thromboxane analogue (U46619), adjusted to maintain mean pulmonary artery pressure (MPAP) at 40 mm Hg. The effects of the different treatments on MPAP and pulmonary resistances were determined. In the first part of the study, we determined the dose-response to increased NO concentrations from 5 to 40 ppm. This showed a maximum pulmonary effect with NO 5 ppm, but with no systemic effects. The effect of NO 10 ppm was then compared with two i.v. drugs. Nitroglycerin was less effective than NO on pulmonary vessels but induced significant arterial hypotension. Pulmonary vasodilatation induced by ciloprost was greater than that by NO but with the same side effects as nitroglycerin on systemic variables. We also found that the combination of NO and nitroglycerin had the same pulmonary effects as NO 10 ppm but that adding ciloprost to NO decreased pulmonary pressures significantly more than either drug used alone. We conclude that inhaled NO may be usefully combined with i.v. ciloprost but not with i.v. nitroglycerin.


Hypertension, Pulmonary/drug therapy , Nitric Oxide/therapeutic use , Vasodilator Agents/therapeutic use , Administration, Inhalation , Animals , Dose-Response Relationship, Drug , Drug Therapy, Combination , Female , Iloprost/therapeutic use , Infusions, Intravenous , Nitroglycerin/therapeutic use , Swine
17.
J Hepatol ; 24(6): 747-52, 1996 Jun.
Article En | MEDLINE | ID: mdl-8835751

BACKGROUND/AIMS: Although the cardiac output is increased in liver cirrhosis, some degree of cardiac failure could coexist as suggested by human investigations showing cardiac enlargement in cirrhosis and by animal studies describing a limited response to fluid loading in the cirrhotic rat. Endotoxemia induces similar hemodynamic changes during the septic shock. This septic cardiomyopathy has been attributed to an increased secretion of nitric oxide by the myocytes. In this study, we aimed to verify if cirrhotic cardiomyopathy was present in the rat with biliary cirrhosis, and if it could be related to abnormal nitric oxide secretion. METHODS: We therefore compared the coronary pressure, the systolic ventricular pressure and the peak rate of rise of the left ventricular pressure obtained from isolated hearts perfused with a modified Langendorff apparatus in control rats and in cirrhotic rats obtained by bile duct ligation. The variations occurring after inhibition of nitric oxide synthesis by the addition of NG monomethyl-L-arginine (10(-6)M) to the perfusing Krebs-Ringer solution were also studied in both groups. RESULTS: We found that the coronary pressure and the contractility of the cirrhotic hearts decreased significantly when compared to the controls. Inhibition of the nitric oxide synthesis increased those values significantly when the hearts were obtained from cirrhotic animals. This was not observed in the control group. CONCLUSIONS: Our data suggest that the cardiac modifications induced by the cirrhosis in the studied parameters are related to nitric oxide.


Ascites/metabolism , Heart Failure/physiopathology , Liver Cirrhosis, Biliary/metabolism , Nitric Oxide/biosynthesis , Animals , Ascites/complications , Cardiac Output/drug effects , Coronary Vessels/drug effects , Coronary Vessels/physiopathology , Enzyme Inhibitors/pharmacology , Heart Failure/etiology , Heart Failure/metabolism , Liver Cirrhosis, Biliary/complications , Liver Cirrhosis, Biliary/physiopathology , Male , Myocardial Contraction/drug effects , Nitric Oxide/antagonists & inhibitors , Rats , Rats, Sprague-Dawley , omega-N-Methylarginine/pharmacology
18.
Eur J Clin Pharmacol ; 50(1-2): 91-6, 1996.
Article En | MEDLINE | ID: mdl-8739817

OBJECTIVE: Results from clinical pharmacokinetic studies of propofol indicate that this i.v. anaesthetic agent may undergo significant extrahepatic glucuronidation. We have investigated whether glucuronidation of propofol takes place in the kidney and/or the gut wall. First, propofol concentrations were measured in arterial (radial artery) and portal venous blood of 12 cirrhotic patients with trans internal jugular porto-systemic shunting (TIPSS). RESULTS: In 7 of the 12 patients arterial propofol concentrations were higher than portal venous concentrations. In the remaining patients, propofol concentrations were higher in the portal vein than the radial artery. Since an additional study in 5 patients anaesthetized with propofol while undergoing cholecystectomy showed propofol and an acid-labile conjugate of it in bile, it is difficult to interpret the results in patients with TIPSS due to the possibility of enterohepatic cycling. Next, in vitro studies with human liver (n = 5), kidney (n = 5) and small intestinal (n = 5) microsomes showed that all three tissues were capable of forming propofol glucuronide. Vmax for propofol glucuronidation was approximately 3 to 3.5 times higher in kidney (5.56 nmol.min-1.mg-1 protein) than liver (1.80 nmol.min-1.mg-1 protein) and small intestine (1.61 nmol.min-1.mg-1 protein). CONCLUSION: Based on these in vitro results, it is concluded that extrahepatic glucuronidation in the small intestine and especially in the kidney may contribute to the overall glucuronidation of propofol in man.


Anesthetics, Intravenous/pharmacokinetics , Intestinal Mucosa/metabolism , Kidney/metabolism , Propofol/pharmacokinetics , Adult , Aged , Bile/metabolism , Biotransformation , Female , Glucuronates/metabolism , Glucuronosyltransferase/metabolism , Humans , In Vitro Techniques , Male , Microsomes/metabolism , Microsomes, Liver/metabolism , Middle Aged , Portal Vein/metabolism
19.
Can J Anaesth ; 42(12): 1126-33, 1995 Dec.
Article En | MEDLINE | ID: mdl-8595689

Progressive familial intrahepatic cholestasis (PFIC) or Byler's disease is one of the most common forms of intrahepatic cholestasis of metabolic and genetic origin. Affected children progress to terminal cirrhosis before adulthood and at present the only curative treatment of PFIC is orthotopic liver transplantation (OLT). We present a retrospective review of 40 general anaesthetics administered in our hospital to 22 patients with PFIC undergoing various procedures. The clinical features of PFIC and the anaesthetic implications of chronic cholestasis in children (malnutrition, cirrhosis, portal hypertension, chronic hypoxaemia) are reviewed.


Anesthesia, General , Cholestasis, Intrahepatic/surgery , Adolescent , Anesthetics, Inhalation , Anesthetics, Intravenous , Child , Child, Preschool , Cholestasis, Intrahepatic/complications , Cholestasis, Intrahepatic/genetics , Chronic Disease , Family Health , Female , Humans , Infant , Liver Cirrhosis/etiology , Male , Preoperative Care , Retrospective Studies
20.
Exp Physiol ; 80(4): 609-17, 1995 Jul.
Article En | MEDLINE | ID: mdl-7576600

The pathogenesis of the vasodilatation associated with liver cirrhosis is not fully understood, but it has recently been postulated that it may be related to an increase in nitric oxide production. The aim of this study was to compare the response of isolated aortic rings from normal and cirrhotic rats to two vasoconstrictors, phenylephrine and U46619, a thromboxane analogue. Biliary cirrhosis was induced by ligation of the common bile duct; a sham operation was performed in control animals. Five weeks later, the aorta was removed and dissected into rings for study in organ chambers. Concentration-response curves were obtained for the two vasoconstrictors from rings with intact endothelium and from rings denuded of endothelium. We found that the vasoconstriction produced by phenylephrine was decreased in cirrhotic vessels both with and without endothelium, but the response to U46619 was not modified by cirrhosis. Concentration-response curves for phenylephrine were also obtained from rings in which the synthesis of nitric oxide and prostaglandins was inhibited by NG-monomethyl-L-arginine and indomethacin, respectively. Nitric oxide synthase inhibition restored normal contractility of the rings with and without endothelium. This beneficial effect was not observed when cyclo-oxygenase activity was blocked with indomethacin. This study suggests that cirrhotic vessels are hyporeactive to vasoconstrictors and that this effect is mediated through increased nitric oxide production. The improvement observed after inhibition of the nitric oxide pathway in denuded rings led us to suggest that cirrhosis also induces nitric oxide synthase in smooth muscle cells, as previously observed by others in septic animals.


Endothelium, Vascular/physiopathology , Liver Cirrhosis, Experimental/physiopathology , Vasoconstriction/physiology , 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid , Animals , Blood Vessels/drug effects , Cyclooxygenase Inhibitors/pharmacology , Male , Nitric Oxide Synthase/antagonists & inhibitors , Phenylephrine/pharmacology , Prostaglandin Endoperoxides, Synthetic/pharmacology , Rats , Rats, Sprague-Dawley , Thromboxane A2/analogs & derivatives , Thromboxane A2/pharmacology , Vasoconstrictor Agents/pharmacology
...